Tward AD - Search Results

1

Hepatocellular carcinoma in Txnip-deficient mice.

Sheth SS, Bodnar JS, Ghazalpour A, Thipphavong CK, Tsutsumi S, Tward AD, Demant P, Kodama T, Aburatani H, Lusis AJ. Sheth SS, et al. Among authors: tward ad. Oncogene. 2006 Jun 15;25(25):3528-36. doi: 10.1038/sj.onc.1209394. Epub 2006 Apr 10. Oncogene. 2006. PMID: 16607285

2

Trypanosoma congolense: paraoxonase 1 prolongs survival of infected mice.

Bhasin KK, Yu JM, Tward A, Shih D, Campbell DA, Lusis AJ. Bhasin KK, et al. Exp Parasitol. 2006 Nov;114(3):240-5. doi: 10.1016/j.exppara.2006.03.010. Epub 2006 May 8. Exp Parasitol. 2006. PMID: 16682028

3

Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice.

Tward A, Xia YR, Wang XP, Shi YS, Park C, Castellani LW, Lusis AJ, Shih DM. Tward A, et al. Circulation. 2002 Jul 23;106(4):484-90. doi: 10.1161/01.cir.0000023623.87083.4f. Circulation. 2002. PMID: 12135950

4

Systemic rather than local heme oxygenase-1 overexpression improves cardiac allograft outcomes in a new transgenic mouse.

Araujo JA, Meng L, Tward AD, Hancock WW, Zhai Y, Lee A, Ishikawa K, Iyer S, Buelow R, Busuttil RW, Shih DM, Lusis AJ, Kupiec-Weglinski JW. Araujo JA, et al. Among authors: tward ad. J Immunol. 2003 Aug 1;171(3):1572-80. doi: 10.4049/jimmunol.171.3.1572. J Immunol. 2003. PMID: 12874251

5

Role of paraoxonase (PON1) status in pesticide sensitivity: genetic and temporal determinants.

Furlong CE, Cole TB, Jarvik GP, Pettan-Brewer C, Geiss GK, Richter RJ, Shih DM, Tward AD, Lusis AJ, Costa LG. Furlong CE, et al. Among authors: tward ad. Neurotoxicology. 2005 Aug;26(4):651-9. doi: 10.1016/j.neuro.2004.08.002. Neurotoxicology. 2005. PMID: 16112327 Review.

6

Paraoxonase 1 (PON1) status and risk of insecticide exposure.

Furlong CE, Cole TB, Walter BJ, Shih DM, Tward A, Lusis AJ, Timchalk C, Richter RJ, Costa LG. Furlong CE, et al. J Biochem Mol Toxicol. 2005;19(3):182-3. doi: 10.1002/jbt.20079. J Biochem Mol Toxicol. 2005. PMID: 15977192 No abstract available.

7

Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds.

Li WF, Costa LG, Richter RJ, Hagen T, Shih DM, Tward A, Lusis AJ, Furlong CE. Li WF, et al. Pharmacogenetics. 2000 Dec;10(9):767-79. doi: 10.1097/00008571-200012000-00002. Pharmacogenetics. 2000. PMID: 11191881

8

Expression of human paraoxonase (PON1) during development.

Cole TB, Jampsa RL, Walter BJ, Arndt TL, Richter RJ, Shih DM, Tward A, Lusis AJ, Jack RM, Costa LG, Furlong CE. Cole TB, et al. Pharmacogenetics. 2003 Jun;13(6):357-64. doi: 10.1097/00008571-200306000-00007. Pharmacogenetics. 2003. PMID: 12777966

9

Toxicity of chlorpyrifos and chlorpyrifos oxon in a transgenic mouse model of the human paraoxonase (PON1) Q192R polymorphism.

Cole TB, Walter BJ, Shih DM, Tward AD, Lusis AJ, Timchalk C, Richter RJ, Costa LG, Furlong CE. Cole TB, et al. Among authors: tward ad. Pharmacogenet Genomics. 2005 Aug;15(8):589-98. doi: 10.1097/01.fpc.0000167327.08034.d2. Pharmacogenet Genomics. 2005. PMID: 16007003

10

Integration of genomic analysis and in vivo transfection to identify sprouty 2 as a candidate tumor suppressor in liver cancer.

Lee SA, Ho C, Roy R, Kosinski C, Patil MA, Tward AD, Fridlyand J, Chen X. Lee SA, et al. Among authors: tward ad. Hepatology. 2008 Apr;47(4):1200-10. doi: 10.1002/hep.22169. Hepatology. 2008. PMID: 18214995

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

45 results

Search Page